Subendocardial Involvement as an Underrecognized LGE Subtype Related to Adverse Outcomes in Hypertrophic Cardiomyopathy

Subendocardial Involvement as an Underrecognized LGE Subtype Related to Adverse Outcomes in Hypertrophic Cardiomyopathy - JIMG September 2023

Description

Late gadolinium enhancement (LGE) has been established as an independent predictor for adverse outcomes in hypertrophic cardiomyopathy (HCM). However, the prevalence and clinical significance of some LGE subtypes have not been well demonstrated.

Editors
Editor-in-Chief
Y.S. Chandrashekhar, MD, DM, FACC

CME Editor
Kenneth A. Ellenbogen, MD

Author
Michael H. Beasley, MD, FACC

Important Dates
Date of Release: September 4, 2023
Term of Approval/Date of CME/MOC Expiration: September 3, 2024

Summary

Availability:

Retired

Cost:

FREE

Credit Offered:

No Credit Offered